

## The use of cardiotonic drugs in neonates

Article (Accepted Version)

Dempsey, Eugene and Rabe, Heike (2019) The use of cardiotonic drugs in neonates. Clinics in Perinatology, 46 (2). pp. 273-290. ISSN 0095-5108

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/84809/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

### **Copyright and reuse:**

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

## The Use of Cardiotonic Drugs in Neonates

<sup>1,2</sup> Dempsey E.M, <sup>3,4</sup> Rabe, H.

<sup>1</sup>Department of Paediatrics and Child Health, Neonatal Intensive Care Unit, University College Cork, Ireland

<sup>2</sup>INFANT, Irish Centre for Fetal and Neonatal Translational research, University College Cork, Ireland

<sup>3</sup>Brighton & Sussex Medical School, University of Sussex, Brighton, UK

<sup>4</sup>Department of Neonatology, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK

[This is the author's accepted version of an article published in Clinics in Perinatology 2019, 46:2, pp 273-290](#)

<https://doi.org/10.1016/j.clp.2019.02.010>

Formatted: Font: Bold

Formatted: Line spacing: single

Please address Correspondence to:

Professor Eugene Dempsey

Department of Paediatrics and Child Health, Neonatal Intensive Care Unit, Wilton, Cork, Ireland.

Telephone: 00353214205040

Email: g.empsey@ucc.ie

**Word Count:** 4049

**References:** 116

**Funding:** This research was partially funded by the European Commission within the 7th Framework Programme (EU FP7/2007-2013) under grant agreement no. 260777 (The HIP Trial) and NEO-CIRC FP7-HEALTH grant (agreement no: 282533). Prof. Dempsey is supported by a Science Foundation Ireland Research Centre Award (INFANT-12/RC/2272).

**Acknowledgments:** The authors would like to acknowledge the support of both the Neocirculation (<http://neocirculation.eu>) and HIP (<https://www.hip-trial.com>) consortia. The authors thank Igor Brbre, clinical librarian, for his help with the literature searches.

**Conflict of Interest:** None

**Keywords:** Low blood pressure, inotrope, inodilator, vasopressor, shock, newborn

**Key Points:**

1. There is a distinct lack of age appropriate cardiotonic drugs and adult formulations are administered without evidence based knowledge on their dosing, safety, efficacy and long term effects.
2. Dopamine remains the most commonly studied and prescribed cardiotonic drug in the neonatal intensive care unit (NICU), but evidence of its effect on end organ perfusion is still lacking.
3. Unlike adult and paediatric critical care, there are significant gaps in knowledge on the use of various cardiotonic drugs in various forms of circulatory failure in the NICU.
4. Performing clinical trials in this area has been challenging and highlights the need for international collaborations, the importance of synergy between the Food and Drug Administration (FDA) and European Medicines Agency (EMA), and the inclusion of industry in the conduct of such trials.

## The Use of Cardiotonic Drugs in Neonates

### 1. Introduction

Inotrope/vasopressors are commonly used in the NICU but with wide variations in practice regarding indications, duration and dosing<sup>1,2</sup>. Following delivery neonates need to adapt their cardiorespiratory system from intrauterine to extrauterine life. During this transition phase, many additional factors can impact this process including timing of umbilical cord clamping, chorioamnionitis, inadequate oxygenation, relative adrenal insufficiency and infection, especially in the most extreme preterm neonates. These interrelated factors often result in a clinical picture characterized by low blood pressure which often is treated with agents such as dopamine, dobutamine, noradrenaline, or corticosteroids<sup>3</sup>.

None of these drugs are currently licensed for the use in preterm or term neonates in spite of the introduction of the Medicines in Children's Acts in several countries<sup>4</sup>. Due to lack of age appropriate formulations, many adult formulations are administered without evidence based knowledge on their safety, efficacy, long term effects of excipients and age appropriate dosing<sup>5,6</sup>. Recently efforts have been initiated to address these deficiencies through funding large randomized trials of inotropes in newborns<sup>7,8</sup>.

Neonatal circulatory failure may occur in many settings. Hypovolemic shock, an infrequent cause of hypotension in the immediate transition period, may be minimised by providing enhanced placental transfusion<sup>9-12</sup>. A recent meta-analysis in preterm neonates receiving placental transfusion found an increased death rate (30%) if the cord was clamped immediately<sup>13</sup>. Long term follow up studies in preterm and term neonates have shown a good safety profile with improved neurodevelopmental outcomes up to 4 years of age<sup>14-17</sup>. In term neonates, circulatory failure may occur in the setting of early onset sepsis, persistent pulmonary hypertension of the newborn, perinatal asphyxia, or as a result of complex congenital cardiac defects. Preterm neonates more often have difficulty in adapting their circulation to extra-uterine life during the first 72 hours of birth. Additional causes for circulatory failure later during their hospital stay include sepsis, necrotizing enterocolitis, and patent ductus arteriosus.

Defining circulatory failure in the newborn poses many challenges for clinicians. Traditionally blood pressure has been the main criteria utilized to define the adequacy of circulatory wellbeing. Numerous blood pressure reference ranges exist, based on gestational age, birth weight and postnatal age. Defining mean blood pressure values below a particular centile, or less than absolute values, less than gestational age equivalent in mmHg has been the most popular definition<sup>3,18</sup> used, but this is too simplistic an approach. More recently other surrogate markers of circulatory failure have been considered, such as base excess and blood lactate as markers of poor tissue perfusion<sup>19,20</sup>. Cardiac function and organ perfusion are now assessed by functional echocardiography, tissue Doppler, pulse plethysmography or near infrared spectroscopy (NIRS)<sup>21</sup>. Treatment algorithms and guidelines often

rely on preferences of local clinicians and their ability to use these additional assessment methods<sup>5</sup>. While a number of groups continue to evaluate the role of additional monitoring tools in haemodynamic assessment<sup>22-25</sup>, further evaluation and clinical trials are necessary before they are routinely incorporated into clinical practice<sup>26</sup> ( see Figure 1). In the following sections we review some of the most commonly prescribed drugs and the conditions in which they are used.

## **2. Inotropic/ Vasopressors/ Inodilators**

### **Dopamine**

Dopamine is the most commonly used inotrope in the treatment of neonatal hypotension<sup>27,28</sup> and is certainly the most studied of all the cardiotonic drugs used in newborn care. There are numerous observational studies of its use in neonates and there are now over 20 randomised controlled trials comparing dopamine to other agents, including placebo. Dopamine works through stimulation of  $\alpha$  and  $\beta$  adrenergic receptors and dopaminergic receptors. The results of these numerous observational studies is a number of postulated effects, suggesting a dose dependent effect on different organs systems<sup>29,30</sup>. The standard administration is by continuous infusion at doses of 2-20 mcg/kg/min with the assumption being that the lower doses of 2-5 mcg/kg/min mainly affect the dopaminergic receptors<sup>31,32</sup>. Further increasing the dose stimulates  $\alpha$  adrenergic receptors causing vasoconstriction and increases in systemic vascular resistance<sup>33</sup>. Although this leads to an increase in cardiac contractility and output<sup>28,34</sup>, evidence from randomised controlled trials suggests that dopamine may have a negative impact on cardiac output through an inotrope/vasopressor imbalance<sup>35-37</sup>. It would be too simple to state that above a certain level one effect is greater than the other, but certainly with increasing doses one is likely to see more vasopressor than inotrope effects and thus the potential to impair end organ perfusion becomes a reality. There is a great deal of overlap in these effects, particularly in critically ill neonates. The choice of an appropriate drug for a specific clinical condition depends on a number of complex interrelated factors including determinants of cardiovascular function and the underlying disease process. There are a number of studies that have assessed the pharmacokinetic (PK) and pharmacodynamic (PD) properties of dopamine in the paediatric population, some of these in neonates<sup>38-46</sup>. The methods of analysis have differed which may account for some of the variability across the studies. The effects on systemic, pulmonary, and cerebral haemodynamics can be monitored at the bedside. Echocardiographic assessment, in particular in the presence of a patent ductus arteriosus<sup>47,48</sup>, has provided some insights into the systemic and pulmonary effects. NIRS has permitted a better understanding of the potential effects on cerebral oxygenation, blood flow, and autoregulation. It has been suggested that dopamine may have negative effects on the cerebrovascular autoregulatory capacity in very preterm neonates<sup>49</sup> which has not been seen by others<sup>50</sup>. In a follow up study, neurodevelopmental outcome at three years may be worse in neonates treated with dopamine versus dobutamine<sup>51</sup>. In a meta-analysis of observational studies, dopamine not only increased BP but also cerebral blood flow<sup>52</sup>. There are no studies comparing dopamine versus placebo in neonates with low blood pressure including evaluating the effects on measures of cerebral perfusion/ cerebral oxygenation. Such studies are warranted.

### **Dobutamine**

Dobutamine is often used as a second line inotropic agent if a maximum dose of dopamine has been reached<sup>27</sup>. It is a synthetic inotrope which directly stimulates  $\alpha$  and  $\beta_1$  receptors in the myocardium. Dobutamine increases cardiac output by increasing contractility and heart rate. In addition, it can have a vasodilatory effect through stimulation of peripheral  $\beta_2$  receptors<sup>53,54</sup>. Dobutamine is administered by continuous infusion with recommended doses of 5-20 mcg/kg/min. Several studies have compared dopamine with dobutamine for circulatory failure and most have demonstrated a greater increase in mean blood pressure with dopamine administration<sup>34,36,55</sup>. However, dobutamine has been observed to increase right and left ventricular output in comparison to dopamine. Comparative studies reported a 21% increase in left ventricular outflow with dobutamine and observed a 14% decrease with dopamine<sup>35,36</sup>. Dobutamine has been shown to increase superior vena cava blood flow in comparison to both dopamine and placebo in neonates with low blood pressure. As with all studies of cardiogenic drugs, very little long term neurodevelopmental outcome data are available.

#### Epinephrine

Epinephrine (Adrenaline) is secreted by the adrenal medulla as an endogenous catecholamine. It stimulates  $\alpha$  and  $\beta$  receptors. It is typically used in protracted neonatal hypotension if dopamine and dobutamine do not achieve the desired effects<sup>6</sup>. However, it is used as a first line agent by some as determined from surveys of practice<sup>2,56</sup>. The effects on the circulation are generally dose dependent. At lower doses the stimulated  $\beta$  receptors cause vasodilation in the systemic and pulmonary circulations. It also increases heart rate and cardiac stroke volume. At increasing doses  $\alpha$  receptors mediated effects are seen resulting in vasoconstriction<sup>28</sup>. The infusion should be administered through a central venous line with a dosing range of 0.05-1.0 mcg/kg/min. Higher doses of have been used but are not recommended<sup>57,58</sup>.

There are very few randomised controlled studies of epinephrine in preterm neonates<sup>59</sup>. Pellicer and colleagues compared dopamine to epinephrine in preterm neonates with low blood pressure. The clinical effects and the side effect profile included a significant increase in heart rate, serum glucose concentration, and rise in lactate after 24-36 hours of continuous infusion compared to dopamine<sup>60</sup>.

#### Norepinephrine

Norepinephrine is an endogenous catecholamine which is released from adrenergic nerve endings. It has strong stimulating effects on  $\alpha$  and  $\beta_1$  receptors and weaker effects on  $\beta_2$  receptors. Noradrenaline has more potent  $\alpha$  mediated effects compared to adrenaline which results in vascular constriction with a subsequent increase in SVR and BP. It may be useful in septic shock, in order to correct the low SVR<sup>61</sup>. Although a number of cohort studies have reported the effects of norepinephrine in preterm neonates<sup>62,63</sup>, randomized controlled trials to confirm these findings are lacking. Norepinephrine might have a role in treating circulatory failure in severe Persistent Pulmonary Hypertension of the Newborn due to a reported pulmonary vasodilator effect<sup>62</sup>. Administration should be via central venous access at doses of 0.02-1 mcg/kg/min.

## Milrinone

Milrinone is a Type III phosphodiesterase inhibitor which acts directly on the myocardium through its inotrope and lusitrope effects. In addition, it can cause vasodilation in the systemic and pulmonary circulation which makes it a drug of choice for treatment of Persistent Pulmonary Hypertension<sup>64</sup>. In a comparative study of levosimendan versus milrinone in neonates undergoing cardiac surgery, cerebral tissue oxygenation measurements were similar for both groups during the immediate 24 hour postoperative phase<sup>65</sup>. In contrast, peripheral oxygenation showed an increase in the levosimendan group and a decrease in the milrinone group together with an increase in lactate. Serial assessments of cardiac function by echocardiography did not demonstrate any differences between both groups.

There is limited evidence for use of milrinone in preterm neonates. It did not prevent the development of a low flow state in high risk preterm neonates when compared to placebo<sup>66,67</sup>. While Halliday and colleagues found no benefit for prophylactic milrinone administration following PDA ligation in preterm neonates, others have found a possible benefit<sup>68-70</sup>. Dosing regimens vary, but milrinone is often started with a loading dose of 50 mcg/kg followed by a continuous infusion. There is one PK study which recommends a bolus infusion of 0.73 mcg/kg/min over 3 hours followed by a continuous infusion of 0.16 mcg/kg/min in preterm neonates<sup>71</sup>. Side effects of tachycardia and hypotension have been described, so it should be used cautiously in the setting of low blood pressure.

## Vasopressin

Vasopressin is an endogenous peptide which is expressed in the hypothalamus. The initial prohormone preprovasopressin is converted to provasopressin and vasopressin in the pituitary gland.<sup>72</sup> It causes vasoconstriction through stimulation of vasopressin V1 receptors in smooth muscle. In addition, it has a vasodilatory effect on cerebral and renal arterioles by stimulation of vasopressin V2 receptors. Overall data on the use in preterm and term neonates is limited and mostly reported as case series<sup>73-78</sup>. Dosing is by continuous infusion of 0.00001-0.003 unit/kg/min. There is quite a variation in the literature regarding the appropriate dosing and bolus administration of 2-20 mcg/kg every 4-6 hours has been reported. Due to the short half-life of 5-15 minutes, the effects last only for about 30-60 minutes. A recent pilot study in 20 very preterm neonates compared vasopressin to dopamine during the first 24 hours of life. Both agents resulted in similar increases in BP but with less tachycardia in the vasopressin group<sup>79</sup>. However, more studies are needed before any recommendations can be made for its routine use in the preterm neonate.

## Levosimendan

Levosimendan is used in adults with acute decompensated congestive heart failure. In neonates it has mainly been used in during cardiac surgery as an inodilator. Levosimendan acts as a calcium sensitizer. It binds to C cardiac troponin and enhances the sensitivity of contractile myofilaments to intracellular calcium in the cardiac muscle cells, thus improving myocardial contractility<sup>80,81</sup>. It activates sarcolemnal K-sensitive adenosine triphosphate channels of vascular smooth muscle cells which has vasodilatory effects. It is thought to have protective effects on ischemia of brain and kidney tissue in neonates. Improved tissue oxygenation measured by NIRS has been reported in a cohort of

neonates undergoing cardiac surgery.<sup>82,83</sup> Infusion doses for neonates range from 0.1-0.2 mcg/kg/min. The potential benefits include increased cardiac output and cardiac index as well as a decrease in heart rate and lactate levels<sup>83</sup>. The side effects include hypotension which needs careful and continuous monitoring. There is no reliable data on the use of levosimendan in preterm neonates and its use as such cannot be recommended at present.

Despite their ongoing use there is surprisingly very little PK and PD data available on the drugs highlighted above. Table 2 provides a summary of the PK/PD studies on dopamine in the neonate. What is evident from this table is the lack of more recent PK/PD data, especially in the very preterm neonate. Smits and colleagues propose an outline on how to use haemodynamic and cerebral monitoring to study pharmacodynamics in neonates<sup>84</sup>. This sort of monitoring will aid in better understanding the effects of inotropes, especially on brain perfusion in very preterm neonates. Figure 1 provides an overview of these potential processes and mechanisms and the monitoring tools available.

### 3. Treatment Scenarios

There are a number of treatment categories in which cardiostatic drugs are administered to the neonate. These include, but are not limited to, the clinical situations outlined below and listed in Table 2. These categories were chosen since these are common situations in which the agents are prescribed in the NICU.

#### 3.1 Transitional Low Blood pressure in the Preterm Neonate

The most common situation in which cardiostatic drugs are administered to neonates is in the first day of life, primarily in preterm neonates with evidence of low blood pressure<sup>85,86</sup>. Uncertainty remains over criteria used to define low blood pressure, criteria upon which to intervene, and what treatment strategy should be employed<sup>87</sup>. Currently, the majority of interventions occur when the blood pressure is below a defined value for a certain period of time, with the most common cardiostatic drug administered being dopamine<sup>27</sup>. This approach is primarily based on familiarity; dopamine has been used as the primary inotrope since the 1970's and when administered will generally result in an increase in blood pressure, which has been the main focus of cardiovascular stability. This approach is now being questioned by many groups, with the focus shifting towards assessment of flow rather than blood pressure<sup>88,89</sup>. However, defining cardiovascular stability during transition remains a key challenge. In a recent observational study by Batton and colleagues which included over 360 preterm neonates born at less than 27 weeks gestation across 16 sites, almost 55% were treated for cardiovascular instability, with over 30% of neonates receiving a cardiostatic drug (mostly dopamine)<sup>85</sup>.

Although dopamine has been the subject of a number of systematic reviews<sup>52,90</sup> and over 20 randomised controlled trials in neonates, significant uncertainty remains<sup>91</sup>. Most studies have been characterized by small numbers, heterogeneous inclusion criteria, and limited short and long-term follow up. While data obtained from these studies is very informative, the limitations need to be acknowledged. A recent observational study by the Epipage



group have highlighted the potential benefits of an interventional approach to low blood pressure during the transitional phase of adaptation, suggesting that neonates who receive an intervention are less likely to sustain brain injury compared to neonates who have an observational approach to care only<sup>92</sup>. It is fair to say that this complex problem remains unresolved, but a number of ongoing or planned studies in this area may shed further light on the problem in the future.

### 3.2 Pulmonary Hypertension (PH)

While the incidence of PH seems to have decreased, and improved management strategies have resulted in fewer neonates requiring more extensive interventions, PH remains a significant problem in newborn care. Supporting the cardiorespiratory system in the setting of PPHN is primarily based on the use of nitric oxide, and the evidence suggests that the number needed to treat to prevent one neonate requiring ECMO is low (five)<sup>93</sup>. However, there is limited data on the use of various cardiotonic agents in the setting of PPHN<sup>94</sup>. The effect of each agent on systemic and pulmonary vascular resistance as well as ductal and atrial shunting needs to be considered. Finally the effects on the peripheral vasculature, in particular cerebral vasculature, also needs to be considered. There is currently no obvious first line agent and the appropriate choice of first line inotropes/inodilators/lusitrope remains unclear.

The role of echocardiography in the setting of PPHN is crucial, both to determine the extent of the problem and also to determine the effect of various intervention strategies<sup>95</sup>. Animal data suggest that epinephrine may be a more suitable agent than dopamine as it has a relatively lower increase in pulmonary vascular resistance compared to dopamine<sup>96</sup>. However, norepinephrine may be a better alternative. The use of milrinone has increased significantly in the NICU<sup>97</sup>, primarily in the setting of PPHN. Although there are a number of case reports and case series, there are no randomized controlled trials addressing the use of milrinone in the setting of PPHN<sup>98-100</sup>. There is currently one small pilot trial enrolling and a larger planned study of milrinone in the setting of congenital diaphragmatic hernia. However, it should be noted that enrollment into such studies may prove difficult. A recent multisite randomized trial of bosentan in the setting of PPHN failed to enroll sufficient numbers of neonates<sup>101</sup>. The reasons included the changing clinical spectrum and difficulties in obtaining timely informed consent. These challenges have afflicted a number of other studies in the area of cardiovascular support and will be discussed in a later section.

### 3.3 Cardiovascular Instability in the Setting of Sepsis

Sepsis remains a common problem in newborn care, predominantly in low resource settings. Septic shock is a condition of inadequate tissue perfusion secondary to cardiovascular dysfunction occurring with suspected or certain systemic infection. It is interesting to note the recent guidance provided by the Surviving Sepsis Campaign. The algorithm addresses a goal directed approach to therapy and the initial inotrope suggested is dopamine. If resistant to therapy, epinephrine should be administered. However, there is very limited evidence to support such an approach, and we would suggest that an alternative approach be given consideration. There have been a number of

trials in the paediatric population, from one month of age upwards comparing dopamine to epinephrine in the setting of sepsis. The consistent finding in this age group is that epinephrine is associated with improved survival in fluid refractory hypotensive shock<sup>102</sup>. Another consideration is the effect of sepsis on drug PK/PD. This is not well understood in the neonate and undoubtedly an individualized approach with particular dosing regimens needs to be carefully considered. One recent trial compared epinephrine and dopamine as a first-line vasoactive drug in 40 neonates with fluid-refractory septic shock in a low resource setting<sup>103</sup>. The initial starting dose of epinephrine was 0.2 µg/kg/min and dopamine 10 µg/kg/min, with subsequent increases of each agent depending on the response. All-cause mortality by 28 days was very high (70%) in the epinephrine vs dopamine group (80%) . The authors concluded that epinephrine (0.2–0.4 µg/kg/min) and dopamine (10–20 µg/kg/min) had comparable efficacy and safety in neonatal septic shock. However mortality was extremely high and generalizability of these findings needs to be interpreted cautiously.

### 3.4 Cardiovascular Instability in the Setting of Perinatal Asphyxia and Therapeutic Hypothermia

The definition of perinatal asphyxia is broad but typically characterized by evidence of metabolic acidosis, low Apgar scores, and the need for initial respiratory support. The primary insult can have implications for cardiovascular function, often in the setting of multiorgan dysfunction. Echocardiography findings after asphyxia include decreased contractility and cardiac output, impaired end diastolic filling, and increased pulmonary artery pressure. The presence of some cardiac biomarkers is associated with altered echocardiographic findings. For neonates with evidence of clinical encephalopathy in the setting of perinatal asphyxia, the primary therapy is therapeutic hypothermia. This has been associated with a reduction in heart rate, stroke volume, and cardiac output and an increase in PH<sup>104-107</sup>. However, these changes do not seem to be associated with an increase in mortality or adverse neurodevelopmental outcome in a meta-analysis of various trials of cooling strategies compared to controls. Therapeutic strategies include use of various agents such as dopamine, dobutamine and epinephrine. There is no consensus as to which agent may be the most appropriate and the majority of the current evidence available is derived from animal studies<sup>108,109</sup>.

## 4. Administration of Agents

There are no neonatal specific cardiogenic formulations and this presents significant challenges, particularly in very preterm neonates where effective and timely delivery of an inotrope infusion may be crucial. There are many problems with the current use of adult preparations. A ready to use neonatal formulation means avoidance of unnecessary delays in formulation preparation. It would also avoid unnecessary dilutions which are both time consuming and also increase the likelihood of contamination or a drug error. Stability testing would be needed with neonatal specific formulations to ensure that the solution has an equal distribution of the drug as opposed to the current method which involves dilutions where there may be unequal distribution resulting in a risk of boluses of

drug being administered. These problems can only be overcome with the use of specific ready to use neonatal formulations.

Even with the use of neonatal specific formulations, other administration challenges include very low infusion rates and relatively large dead space considerations which will result in long lag times before the drug gets to the desired location. The syringe size, the diameter and length of the tubing are other important factors that need to be considered. Upward displacement of the syringe pump results in a potential increase in the flow rate. With lower the infusion rates, the greater the relative bolus delivery of the drug.<sup>110-113</sup> Physicians need to be aware of these potential side effects and minimise their occurrence.

Inotropes as molecules can be quite unstable if exposed to oxygen and diluted in infusion mixtures. A study on the stability of typical Dopamine and Dobutamine infusions made from adult formulations used in the NICU demonstrated two time points of significant changes in the concentration of Dopamine. Time point one was within the first 30 minutes of preparing the infusion and the second time point was after approximately 12 hours after the Dopamine infusion<sup>114</sup>. Drug concentrations fell by more than 7% which is outside the standard tolerance rate. It is therefore suggested to wait for 30 minutes before connecting a new infusion mixture to the neonate for infusion and to change dopamine infusions after 12 hours rather than every 24 hours. However, more frequent changing of inotrope infusions carries their own unwanted side effects and perhaps of more importance is the development of stable neonatal formulations.

## 5. Future Directions

The study of cardiotoxic drugs in the neonate appears to be particularly challenging, especially in comparison to other areas of newborn care. There are no large randomized controlled trials evaluating the efficacy of various agents in the conditions outlined above. This is in stark contrast to the pediatric and adult population where large randomized controlled trials have been performed and have helped to inform practice. There are many potential reasons to explain this dearth of studies. Since there are no neonatal specific formulations available, it is more challenging to perform studies in time sensitive situations. The incidence of the various conditions outlined seems to have decreased somewhat over time, which again makes it more challenging to enroll. Obtaining valid informed consent also remains a major hurdle to recruitment. A number of trials have met challenges in enrollment. These include a study on neonatal hypotension in extreme preterm neonates<sup>115</sup>, a study of corticosteroid in cardiovascular instability in late preterm neonates<sup>116</sup> and a study of bosentan use in PPHN<sup>101</sup>. These serve as a stark reminder of the challenges in conducting studies in this area and highlight the need for international collaborations, the importance of synergy between the FDA and EMA and the inclusion of industry in the conduct of such trials. The role of the International Neonatal Consortium is crucial to facilitating this engagement and ensuring the foundations are established to finally try and answer some of these age old questions with clear and concise evidence.

## References

1. Batton BJ, Li L, Newman NS, et al. Feasibility study of early blood pressure management in extremely preterm infants. *J Pediatr*. 2012;161(1):65-69 e61.
2. Dempsey EM, Barrington KJ. Diagnostic criteria and therapeutic interventions for the hypotensive very low birth weight infant. *J Perinatol*. 2006;26(11):677-681.
3. Faust K, Hartel C, Preuss M, et al. Short-term outcome of very-low-birthweight infants with arterial hypotension in the first 24 h of life. *Arch Dis Child Fetal Neonatal Ed*. 2015;100(5):F388-392.
4. Ruggieri L, Giannuzzi V, Baiardi P, et al. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. *Eur J Pediatr*. 2015;174(4):481-491.
5. Ergenekon E, Rojas-Anaya H, Bravo MC, Kotidis C, Mahoney L, Rabe H. Cardiovascular Drug Therapy for Human Newborn: Review of Pharmacodynamic Data. *Curr Pharm Des*. 2017;23(38):5850-5860.
6. Mahoney L, Crook D, Walter KN, Sherman E, Rabe H. What is the evidence for the use of adrenaline in the treatment of neonatal hypotension? *Cardiovascular & hematological agents in medicinal chemistry*. 2012;10(1):50-98.
7. Dempsey EM. Under pressure to treat? *Arch Dis Child Fetal Neonatal Ed*. 2015;100(5):F380-381.
8. Rabe H, Rojas-Anaya H. Inotropes for preterm babies during the transition period after birth: friend or foe? *Arch Dis Child Fetal Neonatal Ed*. 2017;102(6):F547-F550.
9. Katheria AC, Lakshminrusimha S, Rabe H, McAdams R, Mercer JS. Placental transfusion: a review. *J Perinatol*. 2017;37(2):105-111.
10. Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. *Cochrane Database Syst Rev*. 2012;8:CD003248.
11. McDonald SJ, Middleton P, Dowswell T, Morris PS. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. *Cochrane Database Syst Rev*. 2013;7:CD004074.
12. Finn D, Roehr CC, Ryan CA, Dempsey EM. Optimising Intravenous Volume Resuscitation of the Newborn in the Delivery Room: Practical Considerations and Gaps in Knowledge. *Neonatology*. 2017;112(2):163-171.
13. Fogarty M, Osborn DA, Askie L, et al. Delayed vs early umbilical cord clamping for preterm infants: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2018;218(1):1-18.
14. Al-Wassia H, Shah PS. Efficacy and safety of umbilical cord milking at birth: a systematic review and meta-analysis. *JAMA pediatrics*. 2015;169(1):18-25.
15. Andersson O, Hellstrom-Westas L, Andersson D, Clausen J, Domellof M. Effects of delayed compared with early umbilical cord clamping on maternal postpartum hemorrhage and cord blood gas sampling: a randomized trial. *Acta Obstet Gynecol Scand*. 2013;92(5):567-574.
16. Ghavam S, Batra D, Mercer J, et al. Effects of placental transfusion in extremely low birthweight infants: meta-analysis of long- and short-term outcomes. *Transfusion*. 2014;54(4):1192-1198.
17. Katheria AC, Lakshminrusimha S, Rabe H, McAdams R, Mercer JS. Placental transfusion: a review. *J Perinatol*. 2016.
18. Farrugia R, Rojas H, Rabe H. Diagnosis and management of hypotension in neonates. *Future cardiology*. 2013;9(5):669-679.
19. de Boode WP. Clinical monitoring of systemic hemodynamics in critically ill newborns. *Early Hum Dev*. 2010;86(3):137-141.
20. Osborn DA, Evans N, Kluckow M. Clinical detection of low upper body blood flow in very premature infants using blood pressure, capillary refill time, and central-peripheral temperature difference. *Arch Dis Child Fetal Neonatal Ed*. 2004;89(2):F168-173.
21. Dempsey EM, El-Khuffash AF. Objective cardiovascular assessment in the neonatal intensive care unit. *Arch Dis Child Fetal Neonatal Ed*. 2018;103(1):F72-F77.
22. Van Laere D, Voeten M, JM OT, Dempsey E. Monitoring Circulation During Transition in Extreme Low Gestational Age Newborns: What's on the Horizon? *Front Pediatr*. 2018;6:74.
23. Rodriguez Sanchez de la Blanca A, Sanchez Luna M, Gonzalez Pacheco N, Arriaga Redondo M, Navarro Patino N. Electrical velocimetry for non-invasive monitoring of the closure of the ductus arteriosus in preterm infants. *Eur J Pediatr*. 2018;177(2):229-235.
24. Papadhima I, Louis D, Purna J, et al. Targeted neonatal echocardiography (TNE) consult service in a large tertiary perinatal center in Canada. *J Perinatol*. 2018.

25. de Boode WP, van der Lee R, Eriksen BH, et al. The role of Neonatologist Performed Echocardiography in the assessment and management of neonatal shock. *Pediatr Res*. 2018;84(Suppl 1):57-67.
26. da Costa CS, Greisen G, Austin T. Is near-infrared spectroscopy clinically useful in the preterm infant? *Arch Dis Child Fetal Neonatal Ed*. 2015;100(6):F558-561.
27. Stranak Z, Semberova J, Barrington K, et al. International survey on diagnosis and management of hypotension in extremely preterm babies. *Eur J Pediatr*. 2014.
28. Subhedar NV. Treatment of hypotension in newborns. *Semin Neonatol*. 2003;8(6):413-423.
29. Hentschel R, Hensel D, Brune T, Rabe H, Jorch G. Impact on blood pressure and intestinal perfusion of dobutamine or dopamine in hypotensive preterm infants. *Biol Neonate*. 1995;68(5):318-324.
30. Lundstrom K, Pryds O, Greisen G. The haemodynamic effects of dopamine and volume expansion in sick preterm infants. *Early Hum Dev*. 2000;57(2):157-163.
31. Seri I, Abbasi S, Wood DC, Gerdes JS. Regional hemodynamic effects of dopamine in the sick preterm neonate. *J Pediatr*. 1998;133(6):728-734.
32. Seri I, Rudas G, Bors Z, Kanyicska B, Tulassay T. Effects of low-dose dopamine infusion on cardiovascular and renal functions, cerebral blood flow, and plasma catecholamine levels in sick preterm neonates. *Pediatr Res*. 1993;34(6):742-749.
33. Zhang J, Penny DJ, Kim NS, Yu VY, Smolich JJ. Mechanisms of blood pressure increase induced by dopamine in hypotensive preterm neonates. *Arch Dis Child Fetal Neonatal Ed*. 1999;81(2):F99-F104.
34. Subhedar NV, Shaw NJ. Dopamine versus dobutamine for hypotensive preterm infants. *Cochrane Database Syst Rev*. 2000(2):CD001242.
35. Roze JC, Tohier C, Maingueneau C, Lefevre M, Mouzard A. Response to dobutamine and dopamine in the hypotensive very preterm infant. *Arch Dis Child*. 1993;69(1 Spec No):59-63.
36. Osborn D, Evans N, Kluckow M. Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. *J Pediatr*. 2002;140(2):183-191.
37. Phillipos EZ BK, Robertson MA. Dopamine versus epinephrine for inotropic support in the neonate: a randomised blinded trial. *Pediatric Research*. 1996(39):A238.
38. Bhatt-Mehta V, Nahata MC. Dopamine and dobutamine in pediatric therapy. *Pharmacotherapy*. 1989;9(5):303-314.
39. Filippi L, Pezzati M, Poggi C, Rossi S, Cecchi A, Santoro C. Dopamine versus dobutamine in very low birthweight infants: endocrine effects. *Arch Dis Child Fetal Neonatal Ed*. 2007;92(5):F367-371.
40. Seri I, Abbasi S, Wood DC, Gerdes JS. Regional hemodynamic effects of dopamine in the indomethacin-treated preterm infant. *J Perinatol*. 2002;22(4):300-305.
41. Seri I, Tulassay T, Kizel J, Machay T, Csomor S. Cardiovascular response to dopamine in hypotensive preterm neonates with severe hyaline membrane disease. *Eur J Pediatr*. 1984;142(1):3-9.
42. Seri I, Tulassay T, Kizel J, et al. Effect of low-dose dopamine infusion on prolactin and thyrotropin secretion in preterm infants with hyaline membrane disease. *Biol Neonate*. 1985;47(6):317-322.
43. Driscoll DJ, Gillette PC, Duff DF, McNamara DG. The hemodynamic effect of dopamine in children. *J Thorac Cardiovasc Surg*. 1979;78(5):765-768.
44. Williams DB, Kiernan PD, Schaff HV, Marsh HM, Danielson GK. The hemodynamic response to dopamine and nitroprusside following right atrium-pulmonary artery bypass (Fontan procedure). *Ann Thorac Surg*. 1982;34(1):51-57.
45. Driscoll DJ. Use of inotropic and chronotropic agents in neonates. *Clin Perinatol*. 1987;14(4):931-949.
46. Eldadah MK, Schwartz PH, Harrison R, Newth CJ. Pharmacokinetics of dopamine in infants and children. *Crit Care Med*. 1991;19(8):1008-1011.
47. Liet JM, Boscher C, Gras-Leguen C, Gournay V, Debillon T, Roze JC. Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus. *J Pediatr*. 2002;140(3):373-375.
48. Bouissou A, Rakza T, Klosowski S, Tourneux P, Vanderborght M, Storme L. Hypotension in preterm infants with significant patent ductus arteriosus: effects of dopamine. *J Pediatr*. 2008;153(6):790-794.
49. Eriksen VR, Hahn GH, Greisen G. Dopamine therapy is associated with impaired cerebral autoregulation in preterm infants. *Acta Paediatr*. 2014;103(12):1221-1226.
50. Wong FY, Barfield CP, Horne RS, Walker AM. Dopamine therapy promotes cerebral flow-metabolism coupling in preterm infants. *Intensive Care Med*. 2009;35(10):1777-1782.
51. Osborn DA, Evans N, Kluckow M, Bowen JR, Rieger I. Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. *Pediatrics*. 2007;120(2):372-380.

52. Sassano-Higgins S, Friedlich P, Seri I. A meta-analysis of dopamine use in hypotensive preterm infants: blood pressure and cerebral hemodynamics. *J Perinatol*. 2011;31(10):647-655.
53. Bravo MC, Lopez-Ortego P, Sanchez L, et al. Randomized, Placebo-Controlled Trial of Dobutamine for Low Superior Vena Cava Flow in Infants. *J Pediatr*. 2015;167(3):572-578 e571-572.
54. Mielgo VE, Valls ISA, Lopez-de-Heredia JM, Rabe H, Rey-Santano C. Hemodynamic and metabolic effects of a new pediatric dobutamine formulation in hypoxic newborn pigs. *Pediatr Res*. 2017;81(3):511-518.
55. Klarr JM, Faix RG, Pryce CJ, Bhatt-Mehta V. Randomized, blind trial of dopamine versus dobutamine for treatment of hypotension in preterm infants with respiratory distress syndrome. *J Pediatr*. 1994;125(1):117-122.
56. Dempsey EM, Barrington KJ, Marlow N, et al. Management of hypotension in preterm infants (The HIP Trial): a randomised controlled trial of hypotension management in extremely low gestational age newborns. *Neonatology*. 2014;105(4):275-281.
57. Cheung PY, Barrington KJ. The effects of dopamine and epinephrine on hemodynamics and oxygen metabolism in hypoxic anesthetized piglets. *Crit Care*. 2001;5(3):158-166.
58. Germanakis I, Bender C, Hentschel R, Braun K, Dittrich S, Kececioglu D. Hypercontractile heart failure caused by catecholamine therapy in premature neonates. *Acta Paediatr*. 2003;92(7):836-838.
59. Paradisi M, Osborn DA. Adrenaline for prevention of morbidity and mortality in preterm infants with cardiovascular compromise. *Cochrane Database Syst Rev*. 2004(1):CD003958.
60. Valverde E, Pellicer A, Madero R, Elorza D, Quero J, Cabanas F. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. *Pediatrics*. 2006;117(6):e1213-1222.
61. Rizk MY, Lapointe A, Lefebvre F, Barrington KJ. Norepinephrine infusion improves haemodynamics in the preterm infants during septic shock. *Acta Paediatr*. 2017.
62. Tourneux P, Rakza T, Abazine A, Krim G, Storme L. Noradrenaline for management of septic shock refractory to fluid loading and dopamine or dobutamine in full-term newborn infants. *Acta Paediatr*. 2008;97(2):177-180.
63. Rowcliff K, de Waal K, Mohamed AL, Chaudhari T. Noradrenaline in preterm infants with cardiovascular compromise. *Eur J Pediatr*. 2016;175(12):1967-1973.
64. Furloria M, Aschner JL. Persistent pulmonary hypertension of the newborn. *Semin Fetal Neonatal Med*. 2017;22(4):220-226.
65. Pellicer A, Riera J, Lopez-Ortego P, et al. Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. *Pediatr Res*. 2013;73(1):95-103.
66. Paradisi M, Evans N, Kluckow M, Osborn D, McLachlan AJ. Pilot study of milrinone for low systemic blood flow in very preterm infants. *J Pediatr*. 2006;148(3):306-313.
67. Paradisi M, Evans N, Kluckow M, Osborn D. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants. *J Pediatr*. 2009;154(2):189-195.
68. Sehgal A. Haemodynamically unstable preterm infant: an unresolved management conundrum. *Eur J Pediatr*. 2011;170(10):1237-1245.
69. Jain A, Sahni M, El-Khuffash A, Khadawardi E, Sehgal A, McNamara PJ. Use of targeted neonatal echocardiography to prevent postoperative cardiorespiratory instability after patent ductus arteriosus ligation. *J Pediatr*. 2012;160(4):584-589 e581.
70. El-Khuffash AF, Jain A, Weisz D, Mertens L, McNamara PJ. Assessment and treatment of post patent ductus arteriosus ligation syndrome. *J Pediatr*. 2014;165(1):46-52 e41.
71. Hallik M, Tasa T, Starkopf J, Metsvaht T. Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion. *Neonatology*. 2017;111(1):8-11.
72. Beaulieu MJ. Vasopressin for the treatment of neonatal hypotension. *Neonatal network : NN*. 2013;32(2):120-124.
73. Lechner E, Hofer A, Mair R, Moosbauer W, Sames-Dolzer E, Tulzer G. Arginine-vasopressin in neonates with vasodilatory shock after cardiopulmonary bypass. *Eur J Pediatr*. 2007;166(12):1221-1227.
74. Bidegain M, Greenberg R, Simmons C, Dang C, Cotten CM, Smith PB. Vasopressin for refractory hypotension in extremely low birth weight infants. *J Pediatr*. 2010;157(3):502-504.
75. Ikegami H, Funato M, Tamai H, Wada H, Nabetani M, Nishihara M. Low-dose vasopressin infusion therapy for refractory hypotension in ELBW infants. *Pediatr Int*. 2010;52(3):368-373.
76. Filippi L, Gozzini E, Daniotti M, Pagliai F, Catarzi S, Fiorini P. Rescue treatment with terlipressin in different scenarios of refractory hypotension in newborns and infants. *Pediatr Crit Care Med*. 2011;12(6):e237-241.

77. Shivanna B, Rios D, Rossano J, Fernandes CJ, Pammi M. Vasopressin and its analogues for the treatment of refractory hypotension in neonates. *Cochrane Database Syst Rev*. 2013;3:CD009171.
78. Mohamed A, Nasef N, Shah V, McNamara PJ. Vasopressin as a rescue therapy for refractory pulmonary hypertension in neonates: case series. *Pediatr Crit Care Med*. 2014;15(2):148-154.
79. Rios DR, Kaiser JR. Vasopressin versus Dopamine for Treatment of Hypotension in Extremely Low Birth Weight Infants: A Randomized, Blinded Pilot Study. *J Pediatr*. 2015;166(4):850-855.
80. Bhat BV, Plakkal N. Management of Shock in Neonates. *Indian J Pediatr*. 2015;82(10):923-929.
81. Egan JR, Clarke AJ, Williams S, et al. Levosimendan for low cardiac output: a pediatric experience. *J Intensive Care Med*. 2006;21(3):183-187.
82. Esch J, Joynt C, Manouchehri N, et al. Differential hemodynamic effects of levosimendan in a porcine model of neonatal hypoxia-reoxygenation. *Neonatology*. 2012;101(3):192-200.
83. Ricci Z, Garisto C, Favia I, Vitale V, Di Chiara L, Cogo PE. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial. *Intensive Care Med*. 2012;38(7):1198-1204.
84. Smits A, Thewissen L, Dereymaeker A, Dempsey E, Caicedo A, Naulaers G. The use of hemodynamic and cerebral monitoring to study pharmacodynamics in neonates. *Curr Pharm Des*. 2017.
85. Batton B, Li L, Newman NS, et al. Use of antihypotensive therapies in extremely preterm infants. *Pediatrics*. 2013;131(6):e1865-1873.
86. Laughon M, Bose C, Allred E, et al. Factors associated with treatment for hypotension in extremely low gestational age newborns during the first postnatal week. *Pediatrics*. 2007;119(2):273-280.
87. Dempsey EM, Barrington KJ. Treating hypotension in the preterm infant: when and with what: a critical and systematic review. *J Perinatol*. 2007;27(8):469-478.
88. Giesinger RE, McNamara PJ. Hemodynamic instability in the critically ill neonate: An approach to cardiovascular support based on disease pathophysiology. *Semin Perinatol*. 2016;40(3):174-188.
89. Noori S, Seri I. Evidence-based versus pathophysiology-based approach to diagnosis and treatment of neonatal cardiovascular compromise. *Semin Fetal Neonatal Med*. 2015;20(4):238-245.
90. Osborn DA, Paradisi M, Evans N. The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow. *Cochrane Database Syst Rev*. 2007(1):CD005090.
91. Dempsey EM, Barrington KJ. Evaluation and treatment of hypotension in the preterm infant. *Clin Perinatol*. 2009;36(1):75-85.
92. Durrmeyer X, Marchand-Martin L, Porcher R, et al. Abstention or intervention for isolated hypotension in the first 3 days of life in extremely preterm infants: association with short-term outcomes in the EPIPAGE 2 cohort study. *Arch Dis Child Fetal Neonatal Ed*. 2017;102(6):490-496.
93. Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. *Cochrane Database Syst Rev*. 2017;1:CD000399.
94. Barrington KJ. Common hemodynamic problems in the neonate. *Neonatology*. 2013;103(4):335-340.
95. Mukerji A, Diambomba Y, Lee SK, Jain A. Use of Targeted Neonatal Echocardiography and Focused Cardiac Sonography in Tertiary Neonatal Intensive Care Units: Time to Embrace It? *J Ultrasound Med*. 2016;35(7):1579-1591.
96. Cheung PY, Barrington KJ, Pearson RJ, Bigam DL, Finer NN, Van Aerde JE. Systemic, pulmonary and mesenteric perfusion and oxygenation effects of dopamine and epinephrine. *Am J Respir Crit Care Med*. 1997;155(1):32-37.
97. Rios DR, Moffett BS, Kaiser JR. Trends in pharmacotherapy for neonatal hypotension. *J Pediatr*. 2014;165(4):697-701 e691.
98. McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. *Pediatr Crit Care Med*. 2013;14(1):74-84.
99. James AT, Corcoran JD, McNamara PJ, Franklin O, El-Khuffash AF. The effect of milrinone on right and left ventricular function when used as a rescue therapy for term infants with pulmonary hypertension. *Cardiology in the young*. 2015;1-10.
100. Giaccone A, Zuppa AF, Sood B, et al. Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn. *Am J Perinatol*. 2017;34(8):749-758.
101. Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. *J Pediatr*. 2016;177:90-96 e93.

102. Ventura AM, Shieh HH, Bousoo A, et al. Double-Blind Prospective Randomized Controlled Trial of Dopamine Versus Epinephrine as First-Line Vasoactive Drugs in Pediatric Septic Shock. *Crit Care Med*. 2015;43(11):2292-2302.
103. Baske K, Saini SS, Dutta S, Sundaram V. Epinephrine versus dopamine in neonatal septic shock: a double-blind randomized controlled trial. *Eur J Pediatr*. 2018.
104. Wu TW, Tamrazi B, Soleymani S, Seri I, Noori S. Hemodynamic Changes During Rewarming Phase of Whole-Body Hypothermia Therapy in Neonates with Hypoxic-Ischemic Encephalopathy. *J Pediatr*. 2018;197:68-74 e62.
105. Forman E, Breatnach CR, Ryan S, et al. Non-invasive continuous cardiac output and cerebral perfusion monitoring in term infants with neonatal encephalopathy: Assessment of feasibility and reliability. *Pediatr Res*. 2017.
106. Cavallaro G, Filippi L, Raffaelli G, et al. Heart Rate and Arterial Pressure Changes during Whole-Body Deep Hypothermia. *ISRN pediatrics*. 2013;2013:140213.
107. Gebauer CM, Knuepfer M, Robel-Tillig E, Pulzer F, Vogtmann C. Hemodynamics among neonates with hypoxic-ischemic encephalopathy during whole-body hypothermia and passive rewarming. *Pediatrics*. 2006;117(3):843-850.
108. Cheung PY, Abozaid S, Al-Salam Z, Johnson S, Li Y, Bigam D. Systemic and regional hemodynamic effects of high-dose epinephrine infusion in hypoxic piglets resuscitated with 100% oxygen. *Shock*. 2007;28(4):491-497.
109. Cheung DC, Gill RS, Liu JQ, et al. Vasopressin improves systemic hemodynamics without compromising mesenteric perfusion in the resuscitation of asphyxiated newborn piglets: a dose-response study. *Intensive Care Med*. 2012;38(3):491-498.
110. Schmidt N, Saez C, Seri I, Maturana A. Impact of syringe size on the performance of infusion pumps at low flow rates. *Pediatr Crit Care Med*. 2010;11(2):282-286.
111. Seyberth HW, Kauffman RE. Basics and dynamics of neonatal and pediatric pharmacology. *Handb Exp Pharmacol*. 2011;205:3-49.
112. Sherwin CM, Medicott NJ, Reith DM, Broadbent RS. Intravenous drug delivery in neonates: lessons learnt. *Arch Dis Child*. 2014;99(6):590-594.
113. van der Eijk AC, van Rens RM, Dankelman J, Smit BJ. A literature review on flow-rate variability in neonatal IV therapy. *Paediatric anaesthesia*. 2013;23(1):9-21.
114. Kirupakaran K, Mahoney L, Rabe H, Patel BA. Understanding the Stability of Dopamine and Dobutamine Over 24 h in Simulated Neonatal Ward Conditions. *Paediatr Drugs*. 2017;19(5):487-495.
115. Vain NE, Barrington KJ. Feasibility of evaluating treatment of early hypotension in extremely low birth weight infants. *J Pediatr*. 2012;161(1):4-7.
116. Watterberg KL, Fernandez E, Walsh MC, et al. Barriers to enrollment in a randomized controlled trial of hydrocortisone for cardiovascular insufficiency in term and late preterm newborn infants. *J Perinatol*. 2017;37(11):1220-1223.



Figure 1




Figure 2




Table 1. Overview of inotropes used for treatment of cardiovascular failure in neonates

Drug name	Receptors	Proposed Physiological effects related to cardiovascular failure	Dosing in newborns	Administration
Dopamine	$\beta_1, \beta_2$ agonist, dopaminergic receptors	Increases in HR, blood pressure, myocardial contractility and variable effects on SVR	2-20 mcg/kg/min	Continuous infusion through central venous line
Dobutamine	$\alpha$ and $\beta_1$ agonist, weak effect on $\beta_2$	Increases heart rate, myocardial contractility and stroke volume.	5-20 mcg/kg/min	Continuous infusion via peripheral or central venous line
Epinephrine	$\alpha_1, \alpha_2, \beta_1, \beta_2$ agonist	Increases heart rate and stroke volume, variable effect on systemic vascular resistance	0.05-1.0 mcg/kg/min	Continuous infusion through central venous line
Norepinephrine	$\alpha_1, \alpha_2, \beta_1$ agonist	Increases heart rate, myocardial contractility and vascular resistance causing vasoconstriction and increase in blood pressure.	0.02-1 mcg/kg/min	Continuous infusion through central venous line
Levosimendon	Calcium sensitizer activating sarcolemmal K-sensitive adenosine triphosphate channel at cellular smooth muscle level	Increases cardiac output and cardiac index. Vasodilatory effects, may cause decrease in heart rate and decrease in blood pressure	0.1-0.2 mcg/kg/min	Limited evidence after cardiac surgery.
Milrinone	Type III phosphodiesterase inhibitor	Decrease of pulmonary and systemic vascular resistance, may cause increase in heart rate and decrease in blood pressure.	0.2-1 mcg/kg/min A bolus of 50 mcg/kg may be considered	Continuous infusion through central venous line
Vasopressin	Vasopressin 1 receptors for vasoconstriction in systemic arteries Vasopressin 2 receptors for vasodilation in cerebral, renal and pulmonary circulation	Increase in blood pressure, cardiac output. May decrease pulmonary vascular resistance.	0.00001-0.003 units/kg/min	Continuous infusion through central venous line. Used as rescue treatment in persistent cardiovascular failure during sepsis.

Table 2. Some unanswered questions in the treatment of cardiovascular failure and how echocardiography may influence the choice of agent used. Evidence supporting these interventions is limited and future clinical studies are essential.

Conditions	Typical Echo findings	Possible agents
Preterm transitional low blood pressure	Normal Decreased myocardial contractility Presence of Large PDA	Observation, low dose epinephrine or dopamine Low dose epinephrine or dobutamine Consider NSAID
Persistent Pulmonary Hypertension	Low systemic blood pressure Decreased RV function	Consider epinephrine Consider dobutamine or Milrinone Monitor Blood pressure continuously
Cardiac dysfunction in the setting of sepsis	Decreased contractility Increased pulmonary artery Low systemic blood pressure	Consider epinephrine Consider dobutamine or Milrinone Consider epinephrine, norepinephrine
Cardiac dysfunction in the setting of therapeutic hypothermia	Decreased contractility Increased pulmonary artery Low systemic blood pressure	Consider epinephrine Consider dobutamine or Milrinone Consider epinephrine, norepinephrine

#### Legends for Figure

Figure 1: Monitoring of blood pressure (BP), blood flow, blood flow distribution, and vascular resistance. NIRS, Near-infrared spectroscopy; OBF, organ blood flow; rSO<sub>2</sub>, regional tissue oxygen saturation. (From Soleymani S, Borzage M, Seri I: Hemodynamic monitoring in neonates: advances and challenges. *J Perinatol* 30:S38–S45, 2010. Used with permission from NaturePublishing Group.)

Figure No. 2 The adapted brain circulation model: Overview of the hemodynamic effects on the brain. Interaction between the 3 processes (blood processes, vascular smooth muscle processes and tissue processes) and 3 mechanisms (cerebral autoregulation, blood flow metabolism coupling and cerebral oxygen balance) as well as value of the appropriate monitoring tools. Reproduced with permission from Bentham